
中東およびアフリカのヒトワクチンアジュバント市場予測 2030年 - 地域分析 - タイプ別(粒子アジュバント、エマルジョンアジュバント、複合アジュバントなど)、用途別(インフルエンザ、肝炎、ヒトパピローマウイルス(HPV)など)、エンドユーザー別(製薬およびバイオテクノロジー企業、CMOおよびCROなど)
No. of Pages: 109 | Report Code: BMIRE00030455 | Category: Life Sciences
No. of Pages: 109 | Report Code: BMIRE00030455 | Category: Life Sciences
1. Novartis AG
2. CSL Ltd
3. Seppic SA
4. Croda International Plc
5. Novavax Inc
6. Phibro Animal Health Corp
The Middle East & Africa Human Vaccine Adjuvants Market is valued at US$ 49.18 Million in 2022, it is projected to reach US$ 119.37 Million by 2030.
As per our report Middle East & Africa Human Vaccine Adjuvants Market, the market size is valued at US$ 49.18 Million in 2022, projecting it to reach US$ 119.37 Million by 2030. This translates to a CAGR of approximately 11.7% during the forecast period.
The Middle East & Africa Human Vaccine Adjuvants Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Human Vaccine Adjuvants Market report:
The Middle East & Africa Human Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Human Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Human Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.